Kenneth S. Thress

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015 · 1.5K citations · Full text

Egfr T790m, Oncology, Medicine +9

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden et al. · Journal of Clinical Oncology · 2016 · 836 citations · Full text

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Peter Ballard, James Yates, Zhenfan Yang et al. · Clinical Cancer Research · 2016 · 704 citations

Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham et al. · JAMA Oncology · 2018 · 673 citations · Full text

Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee et al. · Journal of Clinical Oncology · 2017 · 523 citations